Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PVSP Artizen™ is the 9th largest cannabis consumer brand in North America according to MJBiz Magazine, November 2021. Pervasip acquired the Artizen IP and made Artizen the first of possibly many consumer focused brands in our brand arsenal.
https://www.pervasip.net/artizen
$GTCH #AIEYE #Podcast; #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $AI) #artificialintelligence #AI #Stocks #markets #Finance #Business #investing #machinelearning #tech #Technology
https://investorideas.com/news/2022/artificial-intelligence/01191GTCH-AI.asp
$SNGX News: Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
June 1, 2022 (PR Newswire)
Paper published in the Journal Structure
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the binding of its Innate Defense Regulator (IDR), dusquetide, to the p62 protein. Dusquetide has demonstrated anti-infective, anti-tumor and anti-inflammatory actions in multiple animal models by modulating the body's own innate immune system. Dusquetide previously demonstrated significant benefits in reducing the duration of severe oral mucositis (SOM) in a Phase 2 clinical trial and reduction in SOM rates in the per protocol population in a Phase 3 study. In addition to the reduction of SOM, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer (HNC). This was corroborated by more recent findings confirming dusquetide's anti-tumor activity in xenograft models of breast cancer.
Based on the biological proof of principle shown both nonclinically and clinically with dusquetide, a novel synthetic peptide that modulates the body's innate immune system, Soligenix continues to explore product opportunities, both in the reduction of oral mucositis in HNC and as a potential anti-cancer treatment. Dusquetide binds to p62 or SQSTM-1, a scaffold protein implicated in a number of intracellular signaling networks implicated in tumor cell survival, including autophagy. This recent publication elaborates on the direct interaction of dusquetide with p62, as well as some of the direct downstream consequences of that interaction, consistent with its observed anti-infective, anti-tumor and anti-inflammatory activities. This information advances the understanding of dusquetide's novel mechanism of action and supports the development of analogs related to dusquetide.
"Soligenix continues to pursue potential product opportunities with our new chemical entity dusquetide," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With the supportive data from the Phase 2 and 3 oral mucositis trials, and the nonclinical anti-tumor efficacy demonstrated, we will continue to pursue potential partnership opportunities for this novel molecule and its potential analogs."
About Dusquetide
Dusquetide (the active ingredient in SGX942) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens. It also accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- and/or radiation therapy. Preclinical efficacy and safety has been demonstrated in numerous animal disease models including mucositis, colitis, macrophage activation syndrome (MAS) as well as bacterial infections, including melioidosis. Potential anti-tumor activity has been demonstrated in in vitro and in vivo xenograft studies.
SGX942 has demonstrated safety and tolerability in a Phase 1 clinical study in 84 healthy human volunteers. Positive efficacy results were demonstrated in an exploratory Phase 2 clinical study in 111 patients with oral mucositis due to CRT for HNC, including potential long-term ancillary benefits. The Phase 3 multinational, placebo-controlled, randomized study evaluated the impact of dusquetide on the duration of SOM in 268 subjects with squamous cell carcinoma of the oral cavity and oropharynx, receiving CRT. While the Phase 3 clinical study did not achieve the required level of statistical significance (pless-than or equal to 0.05) in its primary endpoint of median duration of SOM, a clinically meaningful reduction was observed, including a statistically significant reduction in the duration of SOM in the per-protocol population (p=0.049), consistent with the findings in the Phase 2 trial.
SGX942 has received Fast Track Designation from the FDA for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in HNC patients, as well as Promising Innovative Medicine designation in the United Kingdom by the Medicines and Healthcare products Regulatory Agency for the treatment of severe oral mucositis in HNC patients receiving CRT. In addition, products containing the same active ingredient, dusquetide, have been granted Fast Track Designation as an adjunctive therapy with other antibacterial drugs, for the treatment of melioidosis and Orphan Drug Designations in the treatment of MAS and the treatment of acute radiation syndrome.
Soligenix has a strong intellectual property position in the IDR technology platform, including composition of matter for dusquetide and related analogs. Dusquetide was developed pursuant to discoveries made by Professors B. Brett Finlay, PhD and Robert Hancock, PhD of the University of British Columbia, Canada. Soligenix has received partial funding from NIH for its oral mucositis clinical studies. The Phase 2 study was supported with a Phase I SBIR grant (#R43DE024032) award, with the Phase 3 study being supported by a Phase II SBIR grant (#R44DE024032) award.
In addition, a high level review of the IDR technology platform is available here.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax(R) will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R). Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
https://c212.net/c/img/favicon.png?sn=PH74370...2022-06-01
View original content:https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html
SOURCE Soligenix, Inc.
$PVSP Pervasip owns 100% of Artizen Corporation (“Artizen Corp”). Artizen Corp’s wholly owned subsidiary, Zen Asset Management LLC (“ZAM”) is a foundational operator that provides the basis for our cannabis related investments. ZAM, a diversified asset management company was founded to acquire, develop, and support companies and technologies in the cannabis industry.
$PVSP As one of Washington’s original cannabis brands, Artizen - branded products are the all-time fourth best-selling in Washington across all product categories, and the all-time third in flower. The commitment to quality and consistency behind Artizen™ has built a substantial following, fueling more than $69 million in wholesale sales to a distribution network with more than 200 retailers, corresponding to more than $200 million in retail value since inception in 2015. ZAM is looking to expand its service into Oregon and California through similar long-term arrangements with cannabis licensees operating in these states
$PVSP With over $17 million in sales annually, Artizen branded cannabis products have established themselves as market leaders in various categories. As the brand is about to be offered in various recreational states, this is just one more award confirming its quality and market acceptance.
$GTCH There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.
https://www.benzinga.com/pressreleases/22/06/g27562448/gbt-is-researching-the-development-of-a-unified-machine-learning-driven-automated-ic-design-enviro
$PVSP Artizen™ Developed in the early days of 2014 on the back of years of experience in medical cannabis, the early founding members decided to grow some of the Northwest’s most well-known strains, add new genetics and create a brand of premium flower products that would eventually establish Artizen as one of the premier consumer brands in Washington State.
$GTCH GBT’s AI based, Motion Detection Wireless Patent has been Granted
https://finance.yahoo.com/news/gbt-ai-based-motion-detection-120000880.html
$PVSP ZAM provides consulting, leasing, intellectual property licensing and other long-term arrangements to cannabis operators, including management of the Artizen™ brand assets
https://www.pervasip.net/zen-asset-management-zam
$PVSP SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced that ArtizenTM is the winner of the esteemed Washington State 2022 Dockside Cannabis Cup.
https://seekingalpha.com/pr/18758372-artizen-winner-of-2022-dockside-cannabis-cup
$SEBFF Corporate Update: Payment of Convertible Interest-in-Kind
https://www.globenewswire.com/news-release/2022/06/02/2455062/0/en/Corporate-Update-Payment-of-Convertible-Interest-in-Kind.html
$AITX Artificial Intelligence Technology Solutions Files for Uplisting to OTCQB
https://www.globenewswire.com/news-release/2022/06/02/2455241/0/en/Artificial-Intelligence-Technology-Solutions-Files-for-Uplisting-to-OTCQB.html
$GTCH As the adoption of artificial intelligence (AI) and its adjacent technologies in the healthcare space increases, so too does its use cases within the sector. In a recent interview with Investorideas.com, Danny Rittman, the CTO of GBT Technologies Inc. (OTC Pink: GTCH) highlighted the way AI is being leveraged in GBT's own healthcare tech IP's, and in the healthcare and medicine domain more broadly.
"We've seen AI in healthcare develop rapidly in the past decade or so," Rittman said. "Major corporations, like IBM, Apple and others stepped in and introduced apparatuses like wearables, as well as AI systems in other forms. IBM was one of the first major players with Watson, which was and is still a huge project, providing analytics in the cancer domain and others."
GBT's intelligent health advisory system, codenamed Hippocrates, leverages the company's Avant! AI engine. Rittman explained Hippocrates and how it can be used as an assistant to physicians.
$GTCH "Fundamentally, today’s advanced chips are having smaller devices with smaller geometries. The silicon areas become more compact and crowded which impacts performance, power consumption and reliability. GAA FET technology is expected to provide performance enhancement with lower power consumption, which we believe makes it attractive for design firms. Another important aspect is that GAA FET relaxes some of the problems introduced by the traditional FinFETS. The new transistor structure is designed to provide stronger device gate control which would enable better conductivity and improved electrical characteristics. This is an important factor because at the smaller nodes, we are noticing more variability, particularly for memories. But with new technologies, typically comes uncertainty. With GAA FET we can expect higher potential for variability and design rule challenges, especially with today’s billions of transistors and advanced functionalities ICs. The ever-going demand to consume minimal power and to operate with high performance using GAA FET, could become a major obstacle for design firms, delaying milestones and timelines. GBT plans to develop GAA FET support for all its EDA productivity enhancement software tools with the goal of saving significant design time, enabling IC designers to maintain competitive schedules. We are going to start with our interactive identification and correction of design rule violations program. This tool operates during the construction of an IC layout, providing an on-the-fly feedback about violations. The tool also offers automatic correction of the detected violation and could save major project’s design time. Without the appropriate level of geometrical accuracy within an affordable time frame designers might need many extra months to reach the desired signoff schedule. Design Rule identification and correction process is a critical step during signoff, and without an intelligent productivity technology an enormous amount of pressure is put on designers to achieve design closure in a timely manner. Supporting GAA FET technology will enable IC designers to achieve design closure in a timely manner, meeting or shortening desired schedules and time to market milestones” provided Danny Rittman, the Company’s CTO.
https://seekingalpha.com/pr/18746050-gbt-develops-gate-all-around-fet-gaa-fet-support-for-integrated-circuits-productivity
$PVSP Artizen™ is the 9th largest cannabis consumer brand in North America according to MJBiz Magazine, November 2021. Pervasip acquired the Artizen IP and made Artizen the first of possibly many consumer focused brands in our brand arsenal.
https://www.pervasip.net/artizen
$PVSP With over 200,000 square feet of grow facility space under management, supporting a 30-person distribution center, and licensing the Artizen™ brand to cultivators in Washington State, ZAM is poised to expand its reach across the West coast and into Arizona and other recreational states.
$PVSP Intereactive Chart https://www.barchart.com/stocks/quotes/PVSP/interactive-chart
$GTCH SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), filed a continuation patent application #17736114 on May 4, 2022, for its data and voice communication system, which has been internally assigned the project code name of “Infinia”. The continuation application covers High Frequency (HF) radio communication through ionospheric propagation environment to reach very long distances. The original patent covers innovative AI technology to overcome skip zones, where there is no reception. The core of the continuation patent application is an AI geo-referenced analytics and management concepts enabling continuous, reliable communication, regardless of location, terrain and weather conditions. The described system and method analyze the ionospheric conditions and automatically adjusts frequencies, antenna power, position and additional factors to ensure reliable and clear radio signal. After a successful GEN I prototype development, GBT is currently working on its GEN II release to be used with an AI implementation. GBT believes there may be a target market for this system in smart military and civil communications, remote emergency response and telemedicine. GBT plans to further invest into the Infinia project during 2022, evaluating it for civil and miliary applications.
https://www.barrons.com/articles/gbt-filed-a-continuation-patent-application-for-its-long-range-radio-system-01653393932?mod=md_stockoverview_news
$SNGX has announced a significant development for a patent allowance for thermostabilized vaccines. The issue of transporting vaccines under difficult to maintain temperature conditions is of high importance around the world so it is very good to see SNGX making key progress in this area.
Soligenix Receives US Patent Allowance For Its Thermostabilized Vaccine Platform
May 23, 2022 (Benzinga)
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are directed to unique, proprietary compositions and methods directed to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to filovirus vaccines (as mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus) as well as a SARS-CoV-2 vaccine.
The candidate filovirus vaccines have been previously shown to protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs. Lyophilization of the antigens within monovalent vaccine formulations has also been demonstrated to thermostabilize the antigens at temperatures as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to 12 weeks, enabling storage at ambient temperature. No currently licensed lyophilized vaccine that contains an adjuvant is presented in a single vial format and there are few reports of successfully using nano-emulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s) and a nanoemulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity. This most recent milestone confirms that, in the context of lethal challenge with Sudan ebolavirus, complete protection is maintained with the thermostabilized formulation.
"Filoviruses such as Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain. There are no vaccines for either Sudan or Marburg viruses, while approved vaccines for Zaire ebolavirus are constrained by cold chain logistics. Availability of a single-vial, heat stable vaccine would significantly enhance global public health preparedness or response to a new outbreak, at its source," stated Axel Lehrer, PhD, Associate Professor, Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai?i at Manoa (UHM). "Our work to date has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can then be stored at temperatures exceeding 100 degrees Fahrenheit. Having a vaccine platform such as this available has the potential to accelerate worldwide vaccination campaigns addressing future health emergencies, including other global pandemics as seen with COVID-19."
"Our next generation combined vaccine platform includes three major components: a robust protein manufacturing process that has been demonstrated on multiple protein antigens, a novel nanoemulsion adjuvant which induces broad immunity and a formulation procedure which enables thermostabilization of the combination of adjuvant and antigen in a single vial," stated Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix. "Elements of this vaccine platform have been utilized in our ricin toxin, filovirus and COVID-19 vaccine candidates, indicating its broad applicability. The ability to package more than one vaccine candidate in a single vial platform further adds to their developability, whether as a multivalent or individual monovalent vaccine, particularly against Sudan ebolavirus and Marburg marburgvirus where there are currently no available vaccines."
Work to date has demonstrated the compatibility of lyophilizing both antigen and adjuvant in the same vial, with reconstitution with sterile water for injection immediately prior to use. This simple delivery format, as well as the compatibility with ambient storage, significantly reduces logistical hurdles when vaccinating large groups of individuals as required for example when addressing a global pandemic or for the deployment of vaccines in outbreaks occurring in remote areas or with unreliable power supply.
Under the Company's Public Health Solutions business segment, ongoing collaborations with Dr. Lehrer, have demonstrated the feasibility of developing thermally-stable subunit protein vaccine formulations for filoviruses. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health (NIH) grant R01-AI132323 (awarded to the University of Hawaii) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix).
$PVSP Recognizing the need for consistency, quality and the opportunity to reach customers across state borders, Artizen was spun off into a brand asset and licensed to independent cultivators in Washington State. The brand’s responsibility to its customers required implementation of grow SOPs, genetic road-mapping, branding assets, and various tools needed in support of marketing and selling Artizen™ branded products
$GTCH SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), intelligent wireless motion detection patent, internal code name “Apollo”, was granted on April 12, 2022. The non-provisional patent protects wireless, real time motion detection technology that is governed via neural network algorithms. The Apollo’s AI technology is designed to control and analyze radio wave transmissions and their reflections to construct 3D images and motion video of an object or living entity. The technology is designed to produce a real-time live video, distinguishing between living entities and objects by detecting distinctive patterns and intelligent mapping. Management is exploring various applications of the Apollo technology including computer vision for autonomous vehicles, health monitoring including vitals measurement and fall detection. There may also be an application in the security system market for intruder prevention, concealed object detection at airports and in the military. The technology is designed to works in indoor/outdoor environments, through walls and other mediums. It is expected that the described effective range for the technology can be extended using extender units to cover larger areas. GBT plans to further research the patented technology for advanced applications development in the near future.
https://www.nasdaq.com/press-release/gbts-ai-based-motion-detection-wireless-patent-has-been-granted-2022-05-04
$GTCH SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), filed a continuation patent application #17736114 on May 4, 2022, for its data and voice communication system, which has been internally assigned the project code name of “Infinia”. The continuation application covers High Frequency (HF) radio communication through ionospheric propagation environment to reach very long distances. The original patent covers innovative AI technology to overcome skip zones, where there is no reception. The core of the continuation patent application is an AI geo-referenced analytics and management concepts enabling continuous, reliable communication, regardless of location, terrain and weather conditions. The described system and method analyze the ionospheric conditions and automatically adjusts frequencies, antenna power, position and additional factors to ensure reliable and clear radio signal. After a successful GEN I prototype development, GBT is currently working on its GEN II release to be used with an AI implementation. GBT believes there may be a target market for this system in smart military and civil communications, remote emergency response and telemedicine. GBT plans to further invest into the Infinia project during 2022, evaluating it for civil and miliary applications.
https://www.barrons.com/articles/gbt-filed-a-continuation-patent-application-for-its-long-range-radio-system-01653393932?mod=md_stockoverview_news
$GTCH SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), filed a continuation patent application #17736114 on May 4, 2022, for its data and voice communication system, which has been internally assigned the project code name of “Infinia”. The continuation application covers High Frequency (HF) radio communication through ionospheric propagation environment to reach very long distances. The original patent covers innovative AI technology to overcome skip zones, where there is no reception. The core of the continuation patent application is an AI geo-referenced analytics and management concepts enabling continuous, reliable communication, regardless of location, terrain and weather conditions. The described system and method analyze the ionospheric conditions and automatically adjusts frequencies, antenna power, position and additional factors to ensure reliable and clear radio signal. After a successful GEN I prototype development, GBT is currently working on its GEN II release to be used with an AI implementation. GBT believes there may be a target market for this system in smart military and civil communications, remote emergency response and telemedicine. GBT plans to further invest into the Infinia project during 2022, evaluating it for civil and miliary applications.
https://www.barrons.com/articles/gbt-filed-a-continuation-patent-application-for-its-long-range-radio-system-01653393932?mod=md_stockoverview_news
$PVSP Recognizing the need for consistency, quality and the opportunity to reach customers across state borders, Artizen was spun off into a brand asset and licensed to independent cultivators in Washington State. The brand’s responsibility to its customers required implementation of grow SOPs, genetic road-mapping, branding assets, and various tools needed in support of marketing and selling Artizen™ branded products.
$PVSP DESCRIPTION
We provide business consulting and marketing services to public companies. More than 100 companies have purchased space on our website https://privateequitymarkets.us/. Our website features publicly traded companies and highlights the mining, technology, bio-tech, green-tech and cannabis industries. Services include free listings of press releases and a news feed.
$PVSP Intereactive Chart https://www.barchart.com/stocks/quotes/PVSP/interactive-chart
$PVSP Recognizing the need for consistency, quality and the opportunity to reach customers across state borders, Artizen was spun off into a brand asset and licensed to independent cultivators in Washington State. The brand’s responsibility to its customers required implementation of grow SOPs, genetic road-mapping, branding assets, and various tools needed in support of marketing and selling Artizen™ branded products.
$PVSP ZAM is a diversified asset management company, founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM provides services to several customers in Washington State, including four licensed cultivation facilities and one licensed processing facility, under a series of consulting, leasing, intellectual property licensing and other long-term agreements. ZAM is also responsible for development and licensing of one of the most successful cannabis brands, Artizen™.
The first independent cultivator’s flagship facility was custom designed and built in Lacey, Washington in 2014. Artizen branded products were licensed to and sold from this facility as early as 2015. The strain collection launched during that time immediately caught the attention of connoisseurs and experienced shop owners and budtenders — folks who know premium cannabis.
$PVSP partnered with a national cultivation group in its effort to upgrade all facilities and grow SOPs with an objective to increase per square foot output by 50%
$PVSP shareholders: We are pleased to announce we are in the final phase of closing a strategic partnership that management believes will add an enormous amount of revenue to our bottom line. We look forward to announcing the details soon. Stay tuned!"
Hello $PVSP shareholders: We are pleased to announce we are in the final phase of closing a strategic partnership that management believes will add an enormous amount of revenue to our bottom line. We look forward to announcing the details soon. Stay tuned!
— Pervasip Corp (@PervasipC) April 19, 2022
$PVSP Artizen™ is the 9th largest cannabis consumer brand in North America according to MJBiz Magazine, November 2021. Pervasip acquired the Artizen IP and made Artizen the first of possibly many consumer focused brands in our brand arsenal.
https://www.pervasip.net/artizen
$PVSP Pervasip owns 100% of Artizen Corporation (“Artizen Corp”). Artizen Corp’s wholly owned subsidiary, Zen Asset Management LLC (“ZAM”) is a foundational operator that provides the basis for our cannabis related investments. ZAM, a diversified asset management company was founded to acquire, develop, and support companies and technologies in the cannabis industry.
$PVSP SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced that ArtizenTM is the winner of the esteemed Washington State 2022 Dockside Cannabis Cup.
https://seekingalpha.com/pr/18758372-artizen-winner-of-2022-dockside-cannabis-cup
$GTCH WEST HOLLYWOOD, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), which entered into a revenue sharing agreement with a third party is testing its AI platform – AVANT- AI (https://www.avant-ai.net/) to identify opportunities with respect to e-commerce sales through the world’s biggest online retail platform. The testing under the revenue sharing agreement commenced on March 1, 2022.
The e-commerce platform can be used via the following link:
https://www.amazon.com/s?me=A21C579I9MM2U0&marketplaceID=ATVPDKIKX0
https://www.nasdaq.com/press-release/gbt-commenced-operations-of-it-e-commerce-platform-2022-03-14
$PVSP Artizen™ is the 9th largest cannabis consumer brand in North America according to MJBiz Magazine, November 2021. Pervasip acquired the Artizen IP and made Artizen the first of possibly many consumer focused brands in our brand arsenal.
https://www.pervasip.net/artizen
$SNGX News: Soligenix to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 (PR Newswire)
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference. The conference will be held May 23 through 26, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Tuesday, May 24 at 7AM ET. To view the presentation, please go to https://journey.ct.events/view/854b33a1-dbee-4dbb-9a35-e3239dfbc75c. The presentation will be archived there for 90 days. For more information about the H.C. Wainwright Global Investment Conference, please refer to the conference website at https://hcwevents.com/globalconference/.
Key members of Soligenix management will hold one-on-one meetings throughout the conference. Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platform.
If you are unable to attend the conferences and would like to schedule a meeting with management, please contact ir@soligenix.com.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax(R) will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R). Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
https://c212.net/c/img/favicon.png?sn=PH60537&sd=2022-05-18
View original content: https://www.prnewswire.com/news-releases/soligenix-to-present-at-the-hc-wainwright-global-investment-conference-301549539.html
SOURCE Soligenix, Inc.
$GTCH SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), will be further broadening its 3D, multiplanar, integrated circuits design and manufacturing continuation patent application, responding to an United States Patent and Trademark Office (“USPTO”) office action. GBT will also seek to protect the original patent’s concepts focusing on semiconductor wafers mounting on vertical and horizontal planes. The original invention design presents a new way to design and manufacture larger size integrated circuits (ICs) to fit advanced analog, digital and mixed IC types on a silicon wafer. The technology that was subject to the patent sought to enable the advanced microchip design and manufacturing within significantly less space which can be a major factor for IC’s manufacturing, performance and cost. It is thought that the invention can be a game changer particularly for integrated circuits that require vast amount of silicon space like memories, CPU, GPU and AI. The Company’s 3D microchip patent was filed on March 5, 2019, and was granted as of December 1, 2020 by the USPTO; U.S. Patent No. 10,854,763. The continuation application, assigned number 17102928, was filed on November 24, 2020. The Company’s intent in filing the continuation is to broaden the protection of its main IP concepts. It is GBT’s goal to further develop advancements in this domain through the use of the 3D, multidimensional design, utilizing more space on the silicon wafer, enabling manufacturing of larger ICs, with higher performance, lower power consumption and cheaper. This technology can be particularly advantageous for fabless design houses to design advanced microchips with much lower cost.
https://seekingalpha.com/pr/18786012-gbt-strengthening-3d-multiplanar-ic-architecture-patent-via-continuation-application
$SNGX News: Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
May 13, 2022 (PR Newswire)
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2022.
Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We remain focused on our significant upcoming milestones for 2022. We anticipate submitting a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing authorization of HyBryte(TM) (SGX301 or synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) in the second half of this year. We expect to initiate a Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in the second half of this year as well. With approximately $22.9 million in cash, not including our non-dilutive government funding, we anticipate having the capital required to achieve our near-term milestones, including NDA filing and expansion into psoriasis with the initiation of the Phase 2a clinical study."
Dr. Schaber continued, "Supported by funding from the National Institute of Allergy and Infectious Diseases, our Public Health Solutions business segment continues to achieve key objectives with our heat stable vaccine platform technology, ThermoVax(R). Recently, we announced results of a booster vaccination study using CiVax(TM) (heat stable COVID-19 subunit vaccine program) in non-human primates (NHPs) demonstrating rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. As always, we continue to evaluate various strategic options, including but not limited to, partnership and merger and acquisition opportunities."
Soligenix Recent Accomplishments
-- On April 19, 2022, the Company announced it had received approximately $1.4 million, net of transaction costs, in non-dilutive funding via multiple government tax programs. To view this press release, please click here.
-- On March 17, 2022, the Company announced the results of a booster vaccination study using CiVax(TM) (heat stable COVID-19 subunit vaccine program) in NHPs demonstrating rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. To view this press release, please click here.
Financial Results - Year Ended March 31, 2022
Soligenix's revenues for the quarter ended March 31, 2022 were $0.2 million as compared to $0.1 million for the quarter ended March 31, 2021. Revenues primarily included payments on government contracts and grants received to support the development of: RiVax(R), our ricin toxin vaccine candidate; SGX943, for treatment of emerging and/or antibiotic-resistant infectious diseases; ThermoVax(R), our thermostabilization platform technology; and CiVax(TM), our vaccine candidate for the prevention of COVID-19.
Soligenix's basic net loss was $4.3 million, or ($0.10) per share, for the quarter ended March 31, 2022, as compared to $2.4 million, or ($0.06) per share, for the quarter ended March 31, 2021. The increase in net loss was primarily attributed to an increase in legal and consulting services associated with the arbitration against Emergent BioSolutions, Inc. and certain of its subsidiaries as well as an increase in research and development expenses associated with preparation of the upcoming HyBryte(TM) NDA filing.
Research and development expenses were $1.7 million as compared to $1.3 million for the quarter ended March 31, 2022 and 2021, respectively. The increase in research and development spending for the quarter ended March 31, 2022 was primarily attributable to the increased expenses associated with preparation of the upcoming HyBryte(TM) NDA filing.
General and administrative expenses were $2.6 million and $1.0 million for the quarter ended March 31, 2022 and 2021, respectively. This increase in general and administrative expenses is primarily attributable to an increase in legal and consulting services associated with the arbitration against Emergent BioSolutions, Inc. and certain of its subsidiaries.
As of March 31, 2022, the Company's cash position was approximately $22.9 million.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax(R) will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R). Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
https://c212.net/c/img/favicon.png?sn=PH54363&sd=2022-05-13
View original content:https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-first-quarter-2022-financial-results-301546777.html
SOURCE Soligenix, Inc.
$PVSP DESCRIPTION
We provide business consulting and marketing services to public companies. More than 100 companies have purchased space on our website https://privateequitymarkets.us/. Our website features publicly traded companies and highlights the mining, technology, bio-tech, green-tech and cannabis industries. Services include free listings of press releases and a news feed.
$PVSP Artizen™ Developed in the early days of 2014 on the back of years of experience in medical cannabis, the early founding members decided to grow some of the Northwest’s most well-known strains, add new genetics and create a brand of premium flower products that would eventually establish Artizen as one of the premier consumer brands in Washington State.
$GTCH Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/GTCH/cheat-sheet
$GTCH SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), will be further broadening its 3D, multiplanar, integrated circuits design and manufacturing continuation patent application, responding to an United States Patent and Trademark Office (“USPTO”) office action. GBT will also seek to protect the original patent’s concepts focusing on semiconductor wafers mounting on vertical and horizontal planes. The original invention design presents a new way to design and manufacture larger size integrated circuits (ICs) to fit advanced analog, digital and mixed IC types on a silicon wafer. The technology that was subject to the patent sought to enable the advanced microchip design and manufacturing within significantly less space which can be a major factor for IC’s manufacturing, performance and cost. It is thought that the invention can be a game changer particularly for integrated circuits that require vast amount of silicon space like memories, CPU, GPU and AI. The Company’s 3D microchip patent was filed on March 5, 2019, and was granted as of December 1, 2020 by the USPTO; U.S. Patent No. 10,854,763. The continuation application, assigned number 17102928, was filed on November 24, 2020. The Company’s intent in filing the continuation is to broaden the protection of its main IP concepts. It is GBT’s goal to further develop advancements in this domain through the use of the 3D, multidimensional design, utilizing more space on the silicon wafer, enabling manufacturing of larger ICs, with higher performance, lower power consumption and cheaper. This technology can be particularly advantageous for fabless design houses to design advanced microchips with much lower cost.
https://seekingalpha.com/pr/18786012-gbt-strengthening-3d-multiplanar-ic-architecture-patent-via-continuation-application
$GTCH Artificial intelligence (AI) is becoming ubiquitous and increasingly indispensable in many sectors, so it is perhaps unsurprising that it is seeing more and more application for military purposes. A report published by Vantage Market Research finds that the global market for AI in Military is projected to grow from $6.62 billion USD in 2021 to $13.71 billion by 2028, while registering a compound annual growth rate (CAGR) of 12.9 percent in the forecast period 2022-28. The report cites AI's use in cybersecurity, communications, threat detection, and more as important market drivers. In a recent interview with Investorideas.com, Danny Rittman, the CTO of GBT Technologies Inc. (OTC Pink: GTCH), highlighted the use of AI in analytics and detection as a key to the market's growth.
https://www.barrons.com/articles/the-ai-eye-podcast-gbt-s-cto-discusses-ai-application-in-military-market-01651579670?mod=md_stockoverview_news
$GTCH "Our Apollo wireless motion detection patent was granted on April 12 and we are pleased to start R&D activities to evaluate its commercialization possibilities. The Apollo patent protects an advanced IP that we believe can be used as an efficient computer vision and in a wide variety of fields. We believe Apollo radio vision system can be used as a wearable-less health, “eyes” for smart vehicles or within a security system to detect concealed objects in airports. The patent’s intelligent computer vision can “see” through walls using machine learning algorithms. Based on RF data analysis, it constructs images and motion video of a scanned area. It is designed to detect and measure a heartbeat, breathing rhythm, a person’s fall, or emotional distress. I Since the technology works during day and night, we believe it can be an efficient technology within military and security applications. We considered Apollo as one of our major innovations and plan to conduct further research and development of intelligent systems based on its concepts.” Provided Danny Rittman, the Company’s CTO.
https://www.marketwatch.com/press-release/gbts-ai-based-motion-detection-wireless-patent-has-been-granted-2022-05-04?mod=mw_quote_news_seemore
$PVSP Artizen On Instagram:
https://www.instagram.com/reel/CVRjKSOBw4c/
Followers
|
839
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48816
|
Created
|
04/12/12
|
Type
|
Free
|
Moderator logical cash | |||
Assistants bra1loga TechnoAnalyst The Bull Investment Group |
Posts Today
|
0
|
Posts (Total)
|
48816
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |